Brent Crude & Eli Lilly and Company

Brent Crude: Brent Crude prices edged higher after dropping significantly, influenced by the resumption of shipping through the Strait of Hormuz and hopes for a peace deal between the United States and Iran. Its price fluctuations are a key factor in global inflation concerns.

Eli Lilly and Company: Eli Lilly and Company>>> advanced after positive trial results for its next-generation obesity drug, retatrutide, which showed benefits beyond weight loss.

Brent Crude: Brent crude oil prices eased due to investor optimism about a potential ceasefire extension between the United States and Iran, which could lead to the reopening of the Strait of Hormuz and increased supply.

Eli Lilly and Company: Eli Lilly and Company>>> advanced after CVS Health>>> announced it would restore coverage for its weight-loss injection, Zepbound, and add its new obesity pill Foundayo.

Brent Crude: Brent Crude prices dropped following reports of a potential deal, reflecting market expectations of improved oil supply through the Strait of Hormuz.

Eli Lilly and Company: Eli Lilly and Company>>> advanced after CVS Health>>> announced it would restore coverage for its weight-loss injection, Zepbound, and add its new obesity pill Foundayo.

Brent Crude: Rose to near $95 per barrel; up from ~$70 before Iran war.

Eli Lilly and Company: Eli Lilly's stock jumped after a committee of the European Medicines Agency recommended one of its medicines for approval, boosting its market performance.

Brent Crude: The price of Brent Crude Oil fell below $76 a barrel, indicating a bearish trend for this commodity.

Eli Lilly and Company: Eli Lilly is partnering with Abridge to streamline care across the health sector.

Brent Crude: Brent Crude prices are reacting to the deal's prospects, with volatility reflecting market uncertainty.

Eli Lilly and Company: Eli Lilly and Company raised its forecast, boosting healthcare stocks. It is not connected to the event.